Literature DB >> 24838680

Human mesenchymal stem cell-derived microvesicles modulate T cell response to islet antigen glutamic acid decarboxylase in patients with type 1 diabetes.

Enrica Favaro1, Andrea Carpanetto, Sara Lamorte, Alberto Fusco, Cristiana Caorsi, Maria C Deregibus, Stefania Bruno, Antonio Amoroso, Mirella Giovarelli, Massimo Porta, Paolo Cavallo Perin, Ciro Tetta, Giovanni Camussi, Maria M Zanone.   

Abstract

AIMS/HYPOTHESIS: Mesenchymal stem cells (MSCs) have been shown to abrogate in vitro the proinflammatory response in type 1 diabetes. The mechanism involves paracrine factors, which may include microvesicles (MVs). We evaluated whether MVs derived from heterologous bone-marrow MSCs exert an immunomodulatory effect on T cell responses against GAD (glutamic acid decarboxylase) antigen in type 1 diabetes.
METHODS: MVs were purified from heterologous human MSCs by differential centrifugation. Peripheral blood mononuclear cells (PBMCs) were obtained from patients with type 1 diabetes at disease onset, and responses to GAD65 stimulation were assessed by IFN-γ enzyme-linked immunosorbent spot analysis. Levels of cytokines and prostaglandin E2 (PGE2) were measured in the supernatant fraction, and T helper 17 (Th17) and regulatory T cell analysis was performed.
RESULTS: MVs were internalised by PBMCs, as assessed by confocal microscopy and flow cytometry analyses. MVs significantly decreased IFN-γ spots and levels in GAD65-stimulated PBMCs, and significantly increased transforming growth factor-β (TGF-β), IL-10, IL-6 and PGE2 levels. Furthermore, MVs decreased the number of Th17 cells and the levels of IL-17, and increased FoxP3(+) regulatory T cells in GAD65-stimulated PBMCs. CONCLUSIONS/
INTERPRETATION: These results provide evidence that MSC-derived MVs can inhibit in vitro a proinflammatory response to an islet antigenic stimulus in type 1 diabetes. The action of MVs involves PGE2 and TGF-β signalling pathways and IL-10 secretion, suggesting a switch to an anti-inflammatory response of T cells.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24838680     DOI: 10.1007/s00125-014-3262-4

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

Review 1.  Type 1 diabetes: new perspectives on disease pathogenesis and treatment.

Authors:  M A Atkinson; G S Eisenbarth
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

2.  Effects of allogeneic bone marrow-derived mesenchymal stem cells on T and B lymphocytes from BXSB mice.

Authors:  Weimin Deng; Qin Han; Lianming Liao; Shengguo You; Hongye Deng; Robert C H Zhao
Journal:  DNA Cell Biol       Date:  2005-07       Impact factor: 3.311

Review 3.  Immunological applications of stem cells in type 1 diabetes.

Authors:  Paolo Fiorina; Julio Voltarelli; Nicholas Zavazava
Journal:  Endocr Rev       Date:  2011-08-23       Impact factor: 19.871

Review 4.  Mesenchymal stem cell exosome: a novel stem cell-based therapy for cardiovascular disease.

Authors:  Ruenn Chai Lai; Tian Sheng Chen; Sai Kiang Lim
Journal:  Regen Med       Date:  2011-07       Impact factor: 3.806

5.  Systemic transforming growth factor-beta1 gene therapy induces Foxp3+ regulatory cells, restores self-tolerance, and facilitates regeneration of beta cell function in overtly diabetic nonobese diabetic mice.

Authors:  Xunrong Luo; Hua Yang; Il Soo Kim; Fludd Saint-Hilaire; Dolca A Thomas; Bishnu P De; Engin Ozkaynak; Thangamani Muthukumar; Wayne W Hancock; Ronald G Crystal; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2005-05-15       Impact factor: 4.939

6.  Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury.

Authors:  Stefano Gatti; Stefania Bruno; Maria Chiara Deregibus; Andrea Sordi; Vincenzo Cantaluppi; Ciro Tetta; Giovanni Camussi
Journal:  Nephrol Dial Transplant       Date:  2011-02-15       Impact factor: 5.992

7.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

8.  Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells.

Authors:  A M Madec; R Mallone; G Afonso; E Abou Mrad; A Mesnier; A Eljaafari; C Thivolet
Journal:  Diabetologia       Date:  2009-05-07       Impact factor: 10.122

9.  Generation of insulin-producing cells from human bone marrow mesenchymal stem cells by genetic manipulation.

Authors:  Ohad Karnieli; Yael Izhar-Prato; Shlomo Bulvik; Shimon Efrat
Journal:  Stem Cells       Date:  2007-07-05       Impact factor: 6.277

10.  Clinical-grade multipotent adult progenitor cells durably control pathogenic T cell responses in human models of transplantation and autoimmunity.

Authors:  James L Reading; Jennie H M Yang; Shereen Sabbah; Ania Skowera; Robin R Knight; Jef Pinxteren; Bart Vaes; Timothy Allsopp; Anthony E Ting; Sarah Busch; Amy Raber; Robert Deans; Timothy I M Tree
Journal:  J Immunol       Date:  2013-04-01       Impact factor: 5.422

View more
  52 in total

1.  Shedding Perspective on Extracellular Vesicle Biology in Diabetes and Associated Metabolic Syndromes.

Authors:  Naureen Javeed
Journal:  Endocrinology       Date:  2019-02-01       Impact factor: 4.736

Review 2.  Extracellular Vesicles in Type 1 Diabetes: Messengers and Regulators.

Authors:  Sarita Negi; Alissa K Rutman; Steven Paraskevas
Journal:  Curr Diab Rep       Date:  2019-07-31       Impact factor: 4.810

Review 3.  Mesenchymal stromal cells to halt the progression of type 1 diabetes?

Authors:  Per-Ola Carlsson; Olle Korsgren; Katarina Le Blanc
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

4.  Role of extracellular vesicles in stem cell biology.

Authors:  Stefania Bruno; Giulia Chiabotto; Enrica Favaro; Maria Chiara Deregibus; Giovanni Camussi
Journal:  Am J Physiol Cell Physiol       Date:  2019-05-15       Impact factor: 4.249

Review 5.  Therapeutic potential of mesenchymal stem/stromal cell-derived secretome and vesicles for lung injury and disease.

Authors:  Airan Liu; Xiwen Zhang; Hongli He; Li Zhou; Yoshifumi Naito; Shinji Sugita; Jae-Woo Lee
Journal:  Expert Opin Biol Ther       Date:  2019-11-18       Impact factor: 4.388

6.  Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro.

Authors:  Lindsay C Davies; Jessica J Alm; Nina Heldring; Guido Moll; Caroline Gavin; Ioannis Batsis; Hong Qian; Mikael Sigvardsson; Bo Nilsson; Lauri E Kyllonen; Kaija T Salmela; Per-Ola Carlsson; Olle Korsgren; Katarina Le Blanc
Journal:  Stem Cells Transl Med       Date:  2016-07-13       Impact factor: 6.940

7.  Mesenchymal Stem Cell Extracellular Vesicles Reverse Sugen/Hypoxia Pulmonary Hypertension in Rats.

Authors:  James R Klinger; Mandy Pereira; Michael Del Tatto; Alexander S Brodsky; Keith Q Wu; Mark S Dooner; Theodore Borgovan; Sicheng Wen; Laura R Goldberg; Jason M Aliotta; Corey E Ventetuolo; Peter J Quesenberry; Olin D Liang
Journal:  Am J Respir Cell Mol Biol       Date:  2020-05       Impact factor: 6.914

Review 8.  Exosomes in perspective: a potential surrogate for stem cell therapy.

Authors:  Ke Ren
Journal:  Odontology       Date:  2018-10-15       Impact factor: 2.634

9.  Human mesenchymal stem cells and derived extracellular vesicles induce regulatory dendritic cells in type 1 diabetic patients.

Authors:  Enrica Favaro; Andrea Carpanetto; Cristiana Caorsi; Mirella Giovarelli; Costanza Angelini; Paolo Cavallo-Perin; Ciro Tetta; Giovanni Camussi; Maria M Zanone
Journal:  Diabetologia       Date:  2015-11-23       Impact factor: 10.122

Review 10.  Stem cell-based therapies for tumors in the brain: are we there yet?

Authors:  Khalid Shah
Journal:  Neuro Oncol       Date:  2016-06-09       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.